TCGA-B6-A400-01A-11R-A239-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 7
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.530
- NOTCH_SIGNALING+0.470
- E2F_TARGETS+0.420
- G2M_CHECKPOINT+0.410
- HEDGEHOG_SIGNALING+0.400
- TNFA_SIGNALING_VIA_NFKB+0.390
- ANGIOGENESIS+0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- WNT_BETA_CATENIN_SIGNALING+0.320
- MYC_TARGETS_V1+0.300
Top 10 suppressed
- PROTEIN_SECRETION-0.510
- ESTROGEN_RESPONSE_EARLY-0.380
- ANDROGEN_RESPONSE-0.320
- BILE_ACID_METABOLISM-0.320
- FATTY_ACID_METABOLISM-0.280
- ADIPOGENESIS-0.270
- PANCREAS_BETA_CELLS-0.270
- PEROXISOME-0.250
- UV_RESPONSE_DN-0.240
- OXIDATIVE_PHOSPHORYLATION-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-37-A5EM-01A-21R-A27Q-07 | — | cohortSQ1 | 0.843 |
| 2 | TCGA-A2-A3XY-01A-11R-A239-07 | — | D | 0.843 |
| 3 | TCGA-A7-A4SE-01A-11R-A266-07 | — | E | 0.828 |
| 4 | TCGA-EW-A1OW-01A-21R-A144-07 | — | E | 0.823 |
| 5 | TCGA-A7-A6VY-01A-12R-A33J-07 | — | E | 0.816 |
| 6 | BS_WJ9H4NZZ | high-grade glioma | — | 0.799 |
| 7 | TCGA-AQ-A04J-01A-02R-A034-07 | — | D | 0.799 |
| 8 | 20050166.TNBC | — | D | 0.790 |
| 9 | SRR12202493 | — | — | 0.789 |
| 10 | TCGA-AO-A0J4-01A-11R-A034-07 | — | E | 0.769 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.470 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.210 | Inavolisib | — uncovered |